OK
OKYO Pharma Limited
OKYO · NASDAQ
$1.33 -1.48% (-$0.02)
1M -9.33%
Market Cap $51.0M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$1.5
12.8% upside
Current Price
$1.33
Undervalued Fair Value Overvalued
According to Bulios Fair Price, OKYO is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
48 /100
Fair P/B 4.14x
PEG N/A
P/E N/A
Growth
-
N/A FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROIC 68.97%
ROA 42.67%
Debt
69 /100
Low Int. coverage -17.87x
Debt/Equity 0.00x
Current ratio 2.43x
Stability
1 /100
Unstable Profitable years 0
Beta 0.05x
EPS volatility 11,489.68%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about OKYO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Robert J. Dempsey
Employees
5
Headquarters
London
Upcoming events
02 DEC
Earnings
Upcoming earnings report